Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

July 12, 2019July 12, 2019

Phase 2 Trial Testing NurOwn Therapy for Progressive MS Adds Third Clinical Site

News

The Phase 2 clinical trial testing BrainStorm Cell Therapeutic’s investigational NurOwn therapy for progressive multiple sclerosis (MS) has added a third clinical site, the company announced. The trial (NCT03799718) now will ... Read more

July 11, 2019July 11, 2019

Targeting Oct1 Protein in T-cells Might Prevent Autoimmune Reactions, MS Mouse Study Finds

News

Targeting a protein found in immune T-cells called Oct1 may help prevent the misguided immune response seen in autoimmune diseases like multiple sclerosis (MS), a study shows. Most importantly, ... Read more

July 9, 2019July 16, 2019

New PET Scan Radiotracer May Help Identify Early Signs of MS Progression, Study Reports

News

A new radiotracer called PBR06, used in positron emission tomography (PET) imaging, helps detect changes in the brain’s grey matter that are linked to progressive forms of multiple sclerosis ... Read more

July 3, 2019July 3, 2019

Rebif Cost-effective and Can Reduce Brain Lesions in RRMS Patients, Data Show

News

Merck KGaA presented new evidence supporting the safety and clinical efficacy of Rebif (interferon beta-1a) for relapsing-remitting multiple sclerosis (RRMS) at the 5th Congress of the European Academy of Neurology (EAN), ... Read more

June 28, 2019June 28, 2019

Less-frequent Dosing with Arbaclofen ER Tablets Decreases Spasticity As Well As Standard Baclofen, MS Trial Data Show

News

Arbaclofen extended-release (ER) tablets taken twice a day can effectively reduce spasticity (muscle stiffness) in patients with multiple sclerosis (MS) with similar potency to that of standard and more-frequently-dosed baclofen (brand name ... Read more

June 19, 2019June 19, 2019

Lemtrada Lowers Levels of Nerve Damage Biomarker Better Than Rebif, Trial Data Show

News

Treatment with Sanofi Genzyme’s Lemtrada (alemtuzumab) for up to two years lowers the levels of serum neurofilament light chain (sNfL), a proposed biomarker of nerve damage, in relapsing-remitting multiple sclerosis (RRMS) patients ... Read more

June 17, 2019June 17, 2019

Human Blood-brain Barrier in a Chip, Created in the Lab, May Help Design New Therapies, Study Shows

News

By tweaking stem cells in a laboratory, researchers were able to generate a model of the human blood-brain barrier (BBB) in a chip. The BBB is a highly selective ... Read more

June 11, 2019June 12, 2019

Aubagio Targets Highly Metabolic Auto-reactive T-Cells, Study Shows

News

Aubagio (teriflunomide), an approved medicine for relapsing forms of multiple sclerosis (MS), specifically targets highly metabolic and more autoreactive T-cells, analysis of the Phase 3 TERI-DYNAMIC clinical trial data shows. The ... Read more

June 5, 2019June 5, 2019

Blocking a Chemical Modification May Help Halt Inflammation in MS, Mouse Study Suggests

News

The pro-inflammatory protein interleukin-17 (IL-17) drives inflammation by promoting a chemical modification, called phosphorylation, in the RNA molecule of the regnase-1 enzyme, a mouse study shows. These findings support ... Read more

June 4, 2019June 11, 2019

Vumerity’s Safety, Effectiveness Bolstered by New Data from EVOLVE-MS-1 Trial

News

Vumerity (diroximel fumarate), taken as a 462 milligram (mg) tablet twice daily, significantly decreases disease activity in patients with relapsing-remitting multiple sclerosis (RRMS), and leads to low rates of gastrointestinal side ... Read more

May 28, 2019May 28, 2019

Experts Gather for Consortium of Multiple Sclerosis Centers Annual Meeting

News

The latest research in multiple sclerosis (MS), along with the most recent advancements in treatment strategies and comprehensive care, will be presented at the Consortium of Multiple Sclerosis Centers ... Read more

May 13, 2019May 13, 2019

#AANAM – Aubagio at Higher Dose Shows Long-term Efficacy in Variety of Patients, Trial Data Show

News

Aubagio taken as 14 milligram (mg) tablet once daily significantly reduces the risk of relapse in people with relapsing multiple sclerosis (MS) over time irrespective of their prior treatment history, ... Read more

May 2, 2019June 3, 2019

Estrogen Promotes Remyelination in Adult Brains of MS Mice, Study Shows

News

Giving estrogen to two different adult mouse models of multiple sclerosis (MS), including the experimental autoimmune encephalomyelitis (EAE) model, promoted remyelination, a new study shows. Exposure to the hormone affected ... Read more

April 18, 2019April 22, 2019

Oligodendrocyte Precursor Cells Disrupt Blood-brain Barrier, Trigger Brain Inflammation in MS, Study Shows

News

Oligodendrocyte precursor cells (OPCs), the cells responsible for myelin production, are unable to migrate into sites of myelin loss in the brain. These cells then cluster and disrupt the ... Read more

April 11, 2019April 11, 2019

Tecfidera Better at Preventing Relapses than Aubagio, Real-world Study Suggests

News

Tecfidera (dimethyl fumarate) is more efficient at preventing relapses, and has a lower discontinuation rate than Aubagio (teriflunomide), according to a Danish study. The study “Comparative effectiveness of teriflunomide and dimethyl ... Read more

April 9, 2019April 9, 2019

U.K. Implements Stricter Rules for Gabapentin, Pregabalin Prescriptions

News

Gabapentin and pregabalin now have more restrictive rules for prescriptions in the United Kingdom. Because of concerns regarding the medications’ misuse, both were classified as class C controlled medicines. ... Read more

March 27, 2019March 29, 2019

FDA Approves Novartis’ Mayzent for Relapsing Forms of Multiple Sclerosis, Including Active SPMS

News

The U.S. Food and Drug Administration (FDA) has approved Novartis’ Mayzent (siponimod) oral tablets for adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (CIS), relapsing-remitting ... Read more

March 8, 2019March 12, 2019

Daily Cup of Flavonoid-rich Cocoa May Help Ease MS Fatigue

News

A daily cup of flavonoid-rich cocoa may help ease fatigue in people with relapsing-remitting multiple sclerosis (RRMS), according to the results of a small clinical trial. The study “A ... Read more

March 6, 2019March 6, 2019

#ACTRIMS2019 – Women Lack Guidance About Pregnancy After MS Diagnosis, Survey Says

News

Women diagnosed with multiple sclerosis (MS) say they lack guidance regarding family planning, pregnancy, and breastfeeding, according to a survey. Sixteen percent of those women also reported they didn’t ... Read more

March 5, 2019March 11, 2019

#ACTRIMS2019 – TG Therapeutics’ Investigational Therapy Ublituximab Posts Positive Data in MS Phase 2 Clinical Trial

Aubagio, News

Full results of a Phase 2 clinical trial testing TG Therapeutics’ lead candidate ublituximab (TG-1101) for relapsing multiple sclerosis (MS) showed that treatment for 48 weeks resulted in a marked reduction ... Read more

March 4, 2019March 4, 2019

#ACTRIMS2019 – Evobrutinib Significantly Reduces Brain Lesions in Relapsing MS, Phase 2 Trial Shows

News

Evobrutinib, Merck KGaA’s oral candidate for relapsing multiple sclerosis (MS), is safe and can significantly reduce active brain lesions over 24 weeks of treatment, results of ongoing Phase 2 study ... Read more

February 25, 2019February 25, 2019

Podocalyxin Helps Protect Blood-brain Barrier During Inflammation, Mouse Study Shows

News

Podocalyxin, a protein found in cells lining the interior of blood vessels, is key for maintaining the integrity of the blood-brain barrier (BBB) in mice with systemic infection, suggesting ... Read more

February 20, 2019March 11, 2019

Early Use of High-efficacy DMTs of Long-term Benefit to MS Patients, Real-world Study Reports

Aubagio, News

Multiple sclerosis (MS) patients given intensive disease-modifying therapies early in their disease course have more favorable long-term outcomes than those treated with an escalating regimen, real-world data shows. The ... Read more

February 6, 2019February 6, 2019

New Research About RhoE Protein Sheds Light on Two Problematic Processes in MS

News

The RhoE protein has been identified as being important for axons’  myelination and extension in the central nervous system, two processes that go awry in diseases like multiple sclerosis ... Read more

February 5, 2019February 6, 2019

Genetic Variants in Inflammasome Genes Influence MS Severity, Progression, Study Suggests

News

Genetic variants that enhance the activity of the NLRP3 inflammasome or the interleukin-1 beta cytokine are linked to higher severity and progression of multiple sclerosis, a study suggests. Previous studies ... Read more

January 30, 2019February 5, 2019

Brain Cells Key to Myelin Grown in Lab and Show Long-Term Survival Essential to Research, Study Reports

News

Stem cells tweaked in the laboratory have allowed researchers, reportedly for a first time, to generate and maintain ball-shaped cultures — called spheroids — of human brain cells in ... Read more

January 29, 2019March 20, 2019

Gilenya Better at Lowering Relapse Rate than Tecfidera or Aubagio, Study Suggests

Aubagio, News

Gilenya is linked to significantly lower annualized relapse rates in relapsing-remitting multiple sclerosis (RRMS) patients compared to Tecfidera or Aubagio, a study suggests. All three therapies showed similar effects on disability ... Read more

January 24, 2019January 24, 2019

Study of Myelin Debris Sheds Light on Brain Inflammation in MS

News

Endothelial cells, those lining the inside of small blood vessels, promote clearance of myelin debris — a common detrimental outcome of demyelinating diseases such as multiple sclerosis (MS) or ... Read more

January 18, 2019January 24, 2019

Blood Stem Cell Transplant Better than DMTs at Reducing Risk of Disease Progression in RRMS

News

Autologous hematopoietic stem cell transplant is better than disease-modifying therapies (DMT) at reducing the risk of disease progression in patients with relapsing-remitting multiple sclerosis (RRMS), results from the MIST ... Read more

January 14, 2019January 14, 2019

Typhoid Vaccine Treats MS by Promoting Regulatory T-cells, Mouse Study Reports

News

Treating a common animal model of multiple sclerosis (MS) with a typhoid vaccine eased disease symptoms by prompting T helper cells to stop production of a pro-inflammatory factor — interleukin (IL)-17 ... Read more

January 10, 2019January 10, 2019

Common Fungal Infection Can Breach the Brain and Impair Memory, Mouse Study Shows

News

Blood infection with the yeast Candida albicans, a type of fungus, can reach the brain and trigger an immune response, a new mouse study shows. Although the fungus can be cleared within ... Read more

January 8, 2019January 10, 2019

Immune Cells in the Gut Can Suppress Brain Inflammation in MS, Pre-clinical Study Finds

News

Immune cells in the intestine may reduce neuroimflammation in multiple sclerosis (MS) patients, a pre-clinical study suggests. Moreover, the augmented number of these cells was sufficient to suppress brain ... Read more

January 3, 2019January 4, 2019

Excess of Single Transcription Factor Appears to Hinder Myelin Repair by Oligodendrocytes, Study Finds

News

Unusually high levels of a transcription factor called paired related homeobox protein 1 (PRRX1) in human oligodendrocyte progenitor cells hinders their ability to respond to the loss of myelin ... Read more

December 21, 2018December 21, 2018

Stem Cell Transplant Lessens Disability and Relapses in RRMS Patients, Phase 2 Trial Shows

News

Treatment with autologous hematopoietic stem cell transplant (aHSCT) led to a sustained decrease in disability and almost no clinical relapses in patients with relapsing-remitting multiple sclerosis (RRMS) who had failed to respond to prior ... Read more

December 20, 2018December 20, 2018

Genetic Variant Linked to MS Affects More Than Immune Cells, Study Finds

News

A genetic variant associated with an increased risk of multiple sclerosis (MS) due to its impact on certain immune system cells can also affect brain cells called astrocytes, a ... Read more

December 10, 2018January 11, 2019

Microglia Cells Diverse with Distinct Subtypes and Certain Ones May Contribute to Inflammation, Study Finds

News

Microglia, the resident immune cells of the brain, were seen to change throughout the lifespan of mice in a study — and to be diverse, with distinct cell subtypes. ... Read more

December 6, 2018December 6, 2018

Fat Spheres Can Deliver DNA into Cells of Central Nervous System, Hold Therapeutic Potential

News

Non-viral vehicles, called niosomes, can deliver DNA to glial cells in the central nervous system, a new study shows. The findings open new avenues for gene therapy and the ... Read more

December 5, 2018December 7, 2018

Aspirin Suppresses MS Symptoms by Preventing Loss of Regulatory T-cells, Mouse Study Shows

News

Aspirin, administered orally at low doses, was sufficient to suppress multiple sclerosis (MS) symptoms in a mouse model of relapsing-remitting MS (RRMS) and chronic MS, a study reports. The ... Read more

December 4, 2018December 7, 2018

Small Molecule Linked to Cells That Control Myelin Production and Repair in Study

News

The formation of new myelin sheaths by oligodendrocytes is impaired in the absence of a small molecule, called Vav3, that oversees pathways regulating the shape of oligodendrocytes, new study ... Read more

November 29, 2018December 4, 2018

Adult Oligodendrocytes May Replenish Myelin Production in MS, Study Suggests

News

Mature, adult oligodendrocytes can reacquire their ability to produce myelin to replace the ones lost in diseases like multiple sclerosis (MS) without undergoing a stem cell-like state, a new ... Read more